ClinicalTrials.gg
CompletedNCT03420989Updated Feb 8, 2023

Elaboration of New Generation Snacks

An interventional study of Active snack food and Control snack food in Snack Food, sponsored by Endocrinology and Clinical Nutrition Research Center, Spain. Completed at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Endocrinology and Clinical Nutrition Research Center, Spain · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

It is a blind randomized clinical trial of nutritional intervention in humans with a snack (seaweeds and carob), compared to a control snack without the bioactive ingredients studied but of similar nutritional composition, to evaluate the effect on the lipid profile, glycemia and Insulin resistance.

Read the detailed description

The design will consist of a double-blind randomized study in adult subjects with metabolic syndrome, who will consume snack (enriched in seaweeds and carob) (50 g / day) vs. conventional snack for 8 weeks.

All the next parameters will be measured/calculated at basal time and after 8 weeks of intervention. The next biochemical parameters will be measured: Total cholesterol, LDL cholesterol, HDL, triglycerides will be analyzed using an enzyme-colorimetric method (Roche Diagnostics , Mannheim, Germany). Glucose will be determined by the method of glucose oxidase (Glucose analyzer 2, Beckman Instruments, Fullerton, California), insulin will be determined by Elisa (ELISA Diagnostic Corporation, Los Angeles, CA) and HOMA will be calculated by the formula Matthew et al. , 1985 (HOMA = (glucose * insulin) / 22.5). Body weight and fat mass by bioimpedance will be measured, too. Blood pressure (Systolic and diastolic blood pressure) will be measured, too. A diet records for 3 days and a satiety scale will be performed at the beginning and end of the intervention period.

02

Conditions studied

  • Snack Food

Keywords

  • carob
  • seaweed
  • snack food
  • obese subjects
03

In context

Lead sponsor

Endocrinology and Clinical Nutrition Research Center, Spain is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • presence of metabolic syndrome by (Adult Treatment Panel III) criteria

Exclusion criteria

Exclusion Criteria:

  • consume supplements (vitamins, minerals or other dietary components),
  • non-restrictive diet
  • known chronic disease (eg diabetes, cardiovascular disease, Inflammatory diseases).
  • active cancer
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Active snack food

    snack food with carob and seaweeds 50 gr per day

    Other: Active snack food

  • Placebo comparator
    Control snack food

    snack food without carob and seaweeds 50 gr per day

    Other: Control snack food

Interventions

  • OtherActive snack food

    snack enriched with seaweeds and carob

  • OtherControl snack food

    the same snack food without seaweeds and carob

06

What researchers measure

Primary outcomes

  1. Lipoproteins

    change in serum lipoprotein levels such as HDL-cholesterol and LDL cholesterol (mg/dl)

    Time frame: change from baseline HDL cholesterol (mg/dl) and LDL cholesterol (mg/dl )levels at 8 weeks

Secondary outcomes

  1. carbohydrate metabolism

    change of seric carbohydrate parameters markers such as fasting glucose levels (mg/dl)

    Time frame: change from baseline fasting glucose levels (mg/dl) at 8 weeks

  2. carbohydrate metabolism

    change of seric carbohydrate parameters markers such as insulin levels (UI/L)

    Time frame: change from baseline insulin levels (UI/L) at 8 weeks

  3. carbohydrate metabolism

    change of seric carbohydrate parameters markers such as HOMA-Insulin resistance (units)

    Time frame: change from baseline HOMA-Insulin Resistance (units) at 8 weeks

  4. Blood pressure

    change of systolic blood pressure (mmHg) and diastolic blood pressure (mmHg)

    Time frame: change from baseline systolic blood pressure (mmHg) and diastolic blood pressure (mmHg) at 8 weeks

07

Study locations

1 site
  • Daniel de Luis Roman
    Valladolid, 47003, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03420989
Lead sponsor
Endocrinology and Clinical Nutrition Research Center, Spain
Responsible party
Daniel de Luis Roman (Medical Doctor, Endocrinology and Clinical Nutrition Research Center, Spain) — Principal investigator
First posted
Feb 5, 2018
Start date
Jan 18, 2018
Primary completion
Sep 18, 2019
Completion
Dec 18, 2019
Last update
Feb 8, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion